ATE365169T1 - Regioselektive synthese von cci-779 - Google Patents
Regioselektive synthese von cci-779Info
- Publication number
- ATE365169T1 ATE365169T1 AT04778398T AT04778398T ATE365169T1 AT E365169 T1 ATE365169 T1 AT E365169T1 AT 04778398 T AT04778398 T AT 04778398T AT 04778398 T AT04778398 T AT 04778398T AT E365169 T1 ATE365169 T1 AT E365169T1
- Authority
- AT
- Austria
- Prior art keywords
- cci
- regioselective synthesis
- regioselective
- synthesis
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229960000235 temsirolimus Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49324903P | 2003-08-07 | 2003-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365169T1 true ATE365169T1 (de) | 2007-07-15 |
Family
ID=34193170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04778398T ATE365169T1 (de) | 2003-08-07 | 2004-07-15 | Regioselektive synthese von cci-779 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7153957B2 (de) |
| EP (1) | EP1658295B1 (de) |
| JP (1) | JP4227649B2 (de) |
| KR (1) | KR20060057605A (de) |
| CN (1) | CN1829722B (de) |
| AR (1) | AR045217A1 (de) |
| AT (1) | ATE365169T1 (de) |
| AU (1) | AU2004265267A1 (de) |
| BR (1) | BRPI0412667A (de) |
| CA (1) | CA2532988A1 (de) |
| CO (1) | CO5650251A2 (de) |
| CR (1) | CR8189A (de) |
| DE (1) | DE602004007145T2 (de) |
| DK (1) | DK1658295T3 (de) |
| EC (1) | ECSP066413A (de) |
| ES (1) | ES2287772T3 (de) |
| IL (1) | IL173134A0 (de) |
| MX (1) | MXPA06000951A (de) |
| NO (1) | NO20060494L (de) |
| PL (1) | PL1658295T3 (de) |
| PT (1) | PT1658295E (de) |
| RU (1) | RU2339639C2 (de) |
| TW (1) | TW200508241A (de) |
| UA (1) | UA83245C2 (de) |
| WO (1) | WO2005016935A2 (de) |
| ZA (1) | ZA200601055B (de) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
| CA2484640C (en) * | 2002-05-15 | 2012-01-17 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| AR040693A1 (es) | 2002-07-30 | 2005-04-13 | Wyeth Corp | Formulaciones parenterales |
| WO2004069159A2 (en) | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| UA84881C2 (ru) * | 2003-09-03 | 2008-12-10 | Уайт | Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его |
| EP1701698B1 (de) * | 2004-01-08 | 2008-01-16 | Wyeth a Corporation of the State of Delaware | Direkt komprimierbare pharmazeutische zusammensetzung für die orale verabreichung von cci-779 |
| JP4224115B2 (ja) | 2004-04-14 | 2009-02-12 | ワイス | ラパマイシン４２−エステル誘導体の位置特異的合成 |
| PL1735321T3 (pl) * | 2004-04-14 | 2009-04-30 | Wyeth Corp | Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała |
| MXPA06011883A (es) | 2004-04-14 | 2006-12-14 | Wyeth Corp | 42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y sintesis enzimatica de dos etapas de 42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionic |
| CN1946852A (zh) * | 2004-04-27 | 2007-04-11 | 惠氏公司 | 利用雷帕霉素特异性甲基化酶标记雷帕霉素 |
| CN101098854B (zh) * | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| CA2577011A1 (en) | 2004-08-10 | 2006-04-13 | Wyeth | Cci-779 derivatives and methods of making same |
| KR20070070184A (ko) | 2004-10-28 | 2007-07-03 | 와이어쓰 | 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도 |
| CA2595766A1 (en) * | 2005-02-09 | 2006-08-17 | Wyeth | Cci-779 polymorph and use thereof |
| RU2007130406A (ru) | 2005-03-02 | 2009-04-10 | Вайет (Us) | Очистка рапамицина |
| MX2007010715A (es) * | 2005-03-02 | 2007-10-12 | Wyeth Corp | Recuperacion de cc-779 a partir de soluciones madre. |
| CN101175757B (zh) | 2005-03-16 | 2012-11-14 | 恩多塞特公司 | 蝶酸及其缀合物的合成和纯化 |
| BRPI0615354A2 (pt) | 2005-08-19 | 2011-05-17 | Endocyte, Inc. | conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso |
| EP2382995A3 (de) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligandenkonjugate von Vincaalkaloiden, Analoga und Derivaten |
| WO2007056175A2 (en) * | 2005-11-04 | 2007-05-18 | Wyeth | 41-methoxy isotope labeled rapamycin 42-ester |
| EP1942937A1 (de) | 2005-11-04 | 2008-07-16 | Wyeth | Antitumor-kombinationen mit mtor-hemmer, herceptin und/oder hki-272 |
| WO2007067566A2 (en) * | 2005-12-07 | 2007-06-14 | Wyeth | Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
| AR058282A1 (es) | 2005-12-07 | 2008-01-30 | Wyeth Corp | Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer. |
| CN101321770A (zh) * | 2005-12-07 | 2008-12-10 | 惠氏公司 | 由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法 |
| US20070142422A1 (en) * | 2005-12-20 | 2007-06-21 | Wyeth | Control of CCI-779 dosage form stability through control of drug substance impurities |
| US20070203169A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| AU2008224988A1 (en) * | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| TW200901989A (en) | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| CN101909441B (zh) | 2007-10-25 | 2015-05-13 | 恩多塞特公司 | 微管蛋白抑制剂及其制备方法 |
| US8754207B2 (en) | 2009-09-25 | 2014-06-17 | Cadila Healthcare Limited | Process for the preparation of rapamycin derivatives |
| WO2011092564A2 (en) * | 2010-01-28 | 2011-08-04 | Fresenius Kabi Oncology Ltd | Process for the preparation of temsirolimus and its intermediates |
| CN102020662B (zh) * | 2011-01-07 | 2013-02-13 | 天津市炜杰科技有限公司 | 一种驮瑞塞尔制备方法 |
| CN102020661B (zh) * | 2011-01-07 | 2013-02-13 | 天津市炜杰科技有限公司 | 一种驮瑞塞尔合成方法 |
| WO2012131019A1 (en) * | 2011-04-01 | 2012-10-04 | Sandoz Ag | Regioselective acylation of rapamycin at the c-42 position |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
| BR112015008365A2 (pt) | 2012-10-16 | 2017-07-04 | Endocyte Inc | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente |
| CN104086564B (zh) * | 2014-07-30 | 2019-02-05 | 江苏奥赛康药业股份有限公司 | 一种高纯度坦罗莫司的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| DE19857765A1 (de) | 1998-12-15 | 2000-06-21 | Clariant Gmbh | Verfahren zur Herstellung von para-Oxadiazolyl-phenyl-boronsäuren |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
-
2004
- 2004-07-15 JP JP2006522574A patent/JP4227649B2/ja not_active Expired - Fee Related
- 2004-07-15 KR KR1020067002610A patent/KR20060057605A/ko not_active Ceased
- 2004-07-15 ES ES04778398T patent/ES2287772T3/es not_active Expired - Lifetime
- 2004-07-15 RU RU2006106910/04A patent/RU2339639C2/ru not_active IP Right Cessation
- 2004-07-15 DK DK04778398T patent/DK1658295T3/da active
- 2004-07-15 CN CN2004800217944A patent/CN1829722B/zh not_active Expired - Fee Related
- 2004-07-15 CA CA002532988A patent/CA2532988A1/en not_active Abandoned
- 2004-07-15 AT AT04778398T patent/ATE365169T1/de not_active IP Right Cessation
- 2004-07-15 PL PL04778398T patent/PL1658295T3/pl unknown
- 2004-07-15 BR BRPI0412667-0A patent/BRPI0412667A/pt not_active IP Right Cessation
- 2004-07-15 AU AU2004265267A patent/AU2004265267A1/en not_active Abandoned
- 2004-07-15 PT PT04778398T patent/PT1658295E/pt unknown
- 2004-07-15 MX MXPA06000951A patent/MXPA06000951A/es active IP Right Grant
- 2004-07-15 DE DE602004007145T patent/DE602004007145T2/de not_active Expired - Fee Related
- 2004-07-15 EP EP04778398A patent/EP1658295B1/de not_active Expired - Lifetime
- 2004-07-15 WO PCT/US2004/022860 patent/WO2005016935A2/en not_active Ceased
- 2004-07-15 UA UAA200602447A patent/UA83245C2/ru unknown
- 2004-07-30 US US10/903,062 patent/US7153957B2/en not_active Expired - Fee Related
- 2004-08-04 AR ARP040102778A patent/AR045217A1/es unknown
- 2004-08-05 TW TW093123422A patent/TW200508241A/zh unknown
-
2006
- 2006-01-12 IL IL173134A patent/IL173134A0/en unknown
- 2006-01-13 CR CR8189A patent/CR8189A/es not_active Application Discontinuation
- 2006-01-31 NO NO20060494A patent/NO20060494L/no not_active Application Discontinuation
- 2006-02-06 ZA ZA200601055A patent/ZA200601055B/en unknown
- 2006-02-28 CO CO06019898A patent/CO5650251A2/es unknown
- 2006-03-07 EC EC2006006413A patent/ECSP066413A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA83245C2 (en) | 2008-06-25 |
| PL1658295T3 (pl) | 2007-11-30 |
| ES2287772T3 (es) | 2007-12-16 |
| MXPA06000951A (es) | 2006-03-30 |
| NO20060494L (no) | 2006-03-06 |
| PT1658295E (pt) | 2007-09-25 |
| RU2339639C2 (ru) | 2008-11-27 |
| JP4227649B2 (ja) | 2009-02-18 |
| RU2006106910A (ru) | 2007-09-20 |
| US20050033046A1 (en) | 2005-02-10 |
| EP1658295B1 (de) | 2007-06-20 |
| EP1658295A2 (de) | 2006-05-24 |
| CN1829722B (zh) | 2010-10-27 |
| AR045217A1 (es) | 2005-10-19 |
| DE602004007145T2 (de) | 2008-02-28 |
| CN1829722A (zh) | 2006-09-06 |
| ZA200601055B (en) | 2008-07-30 |
| US7153957B2 (en) | 2006-12-26 |
| DK1658295T3 (da) | 2007-09-24 |
| CO5650251A2 (es) | 2006-06-30 |
| WO2005016935A2 (en) | 2005-02-24 |
| DE602004007145D1 (de) | 2007-08-02 |
| ECSP066413A (es) | 2006-09-18 |
| TW200508241A (en) | 2005-03-01 |
| WO2005016935A3 (en) | 2005-04-07 |
| JP2007501783A (ja) | 2007-02-01 |
| IL173134A0 (en) | 2006-06-11 |
| AU2004265267A1 (en) | 2005-02-24 |
| CR8189A (es) | 2006-10-04 |
| CA2532988A1 (en) | 2005-02-24 |
| KR20060057605A (ko) | 2006-05-26 |
| BRPI0412667A (pt) | 2006-09-26 |
| HK1085482A1 (en) | 2006-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE365169T1 (de) | Regioselektive synthese von cci-779 | |
| CY2022001I1 (el) | Παραγωγα του uk-2a | |
| ATE359787T1 (de) | Kontrollierte synthese von ziprasidon | |
| ATE521612T1 (de) | Synthese von boronsäureester- und boronsäureverbindungen | |
| EP1685240A4 (de) | Verbesserte verfahren zur in-vitro-proteinsynthese | |
| EP1682529A4 (de) | Verfahren zur synthese von chinolinonverbindungen | |
| EP1848778A4 (de) | Neusynthese von bakteriochlorinen | |
| DK1778618T3 (da) | Syntese af triethylentetraminer | |
| EP1583997A4 (de) | Photoresistentfernung | |
| DZ3268A1 (fr) | Synthese asymetrique de pregabaline | |
| DE602004004287D1 (de) | Selektive synthese von cf3-substituierten pyrimidinen | |
| DE60001510D1 (de) | Regioselektive synthese von rapamycinderivaten | |
| SK4326U (sk) | Farmaceutická kompozícia s predĺženým uvoľňovaním | |
| NO20044664L (no) | Fisher-Tropsch katalysator | |
| DE602006021628D1 (de) | Verbesserte synthese und zubereitungen von duloxetinsalzen | |
| EP1957474A4 (de) | Synthese von ftsz-hemmern | |
| DE60218860D1 (de) | Polymerisate und ihre synthese | |
| EP1863800A4 (de) | Synthese von avrainvillamid, stephacidin b und analoga davon | |
| ATE500249T1 (de) | Synthese von himbacinanaloga | |
| EP1735281A4 (de) | Synthese von indenoisochinolinium-verbindungen und deren verwendung | |
| DE602005005645D1 (de) | Stereoselektive synthese von vitamin-d-analoga | |
| ATE402145T1 (de) | Synthese von pyrrol-2-carbonsäurenitrilen | |
| ATE499348T1 (de) | Stabiler polymorph von bifeprunoxmesilat | |
| EP1534783A4 (de) | Synthese von cis-diolen aus arylsilanen | |
| ATE374742T1 (de) | Synthese von 2-chlormethyl-6- methylbenzoesäureestern |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1658295 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |